Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 285, Issue 33, Pages 25859-25866Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M110.134874
Keywords
-
Categories
Funding
- National Institutes of Health [CA139520, P50CA058204]
- NCI [CA111479]
- United States Department of Defense [PC040121, PC060932]
- University of Texas MD Anderson Cancer Center
Ask authors/readers for more resources
SUMOylation has been shown to modulate DNA replication/repair, cell cycle progression, signal transduction, and the hypoxic response. SUMO (small ubiquitin-like modifier)-specific proteases regulate SUMOylation, but how changes in the expression of these proteases contribute to physiological and/or pathophysiological events remains undefined. Here, we show that SENP1 (sentrin/SUMO-specific protease 1) is highly expressed in human prostate cancer specimens and correlates with hypoxia-inducing factor 1 alpha (HIF1 alpha) expression. Mechanistic studies in a mouse model indicate that androgen-driven expression of murine SENP1 leads to HIF1 alpha stabilization, enhanced vascular endothelial growth factor production, and angiogenesis. Further pathological assessment of the mouse indicates that SENP1 overexpression induces transformation of the normal prostate gland and gradually facilitates the onset of high-grade prostatic intraepithelial neoplasia. Consistent with cell culture studies, SENP1 enhances prostate epithelial cell proliferation via modulating the androgen receptor and cyclin D-1. These results demonstrate that deSUMOylation plays a critical role in prostate pathogenesis through induction of HIF1 alpha-dependent angiogenesis and enhanced cell proliferation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available